Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

UK scientists begin testing BCG vaccine for severe COVID-19 protection

Researchers believe shot could help to protect against severe COVID-19

- PMLiVE

FDA publishes new guidelines for COVID-19 vaccine approval

New rules mean a COVID-19 shot is unlikely to be approved pre-election in the US

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

J&J signs deal with EU for 200 million COVID-19 vaccine doses

EU member states will have an option to secure 200 million additional doses

- PMLiVE

Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

Combination of two antibodies reduced viral load and symptoms of COVID-19

China flag thumb

Experimental Chinese COVID-19 vaccine is safe, according to researchers

Safety data was published on pre-print server medRxiv

- PMLiVE

WHO’s director-general says COVID-19 vaccine may be available by year-end

Remarks were made at a WHO executive board meeting earlier this week

- PMLiVE

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

Study extends into additional sites after positive safety assessment

- PMLiVE

AbbVie’s HIV therapy Kaletra fails to show efficacy in COVID-19

Drug failed to improved condition of hospitalised COVID-19 patients

- PMLiVE

Pfizer and BioNTech’s COVID-19 vaccine begins EMA evaluation

Vaccine is the second to undergo EMA's 'rolling review' process after AstraZeneca/Oxford Uni's candidate

- PMLiVE

Nearly 16,000 coronavirus cases left out of UK’s daily figures between 25 September and 2 October

PHE chief exec says ‘technical issue’ caused unreported coronavirus cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links